Evidence map›Paper›PMID 35263081›Full record

ArticleACS infectious diseases2022

A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant.

Albert To, Teri Ann S Wong, Michael M Lieberman, Karen Thompson, Aquena H Ball, Laurent Pessaint, Jack Greenhouse, Nisrine Daham, Anthony Cook, Brandon Narvaez and 7 more

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Albert ToDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawaii 96813, United States.ORCID 0000-0002-7118-9803
Teri Ann S WongDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawaii 96813, United States.
Michael M LiebermanDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawaii 96813, United States.
Karen ThompsonDepartment of Pathology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawaii 96813, United States.
Aquena H BallDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawaii 96813, United States.
Laurent PessaintBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Jack GreenhouseBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Nisrine DahamBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Anthony CookBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Brandon NarvaezBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Zack FlinchbaughBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Alex Van RyBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Jake Yalley-OgunroBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Hanne Andersen ElyardBIOQUAL, Inc., Rockville, Maryland 20850, United States.
Chih-Yun LaiDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawaii 96813, United States.
Oreola DoniniSoligenix, Inc., Princeton, New Jersey 08540, United States.
Axel T LehrerDepartment of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Ma̅noa, Honolulu, Hawaii 96813, United States.
Bioqual · USUniversity of Hawaiʻi at Mānoa · USSoligenix (United States) · US

Funding

The Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Benjamin C. Fogelgren · 2017 to 2026
$59.5M
Small Grants ProgramP30GM114737 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI NERURKAR, VIVEK RAMCHANDRA · 2015 to 2022
$8.1M
Preclinical Development of a Thermostable Trivalent Filovirus VaccineR01AI132323 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI LEHRER, AXEL T · 2017 to 2021
$6.3M
Training in Cardiovascular Research at the University of HawaiiT32HL115505 · NHLBI · UNIVERSITY OF HAWAII AT MANOA · PI Michelle D Tallquist · 2012 to 2026
$3.8M
NHLBI NIH HHS T32 HL115505NIAID NIH HHS R01 AI132323NIGMS NIH HHS P30 GM114737NIMHD NIH HHS U54 MD007601
6 · The paper itself

Abstract

FDA-approved and emergency use-authorized vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease; however, information on their long-term efficacy and protective breadth against severe acute respiratory syndrome coronavirus 2 variants of concern (VOCs) is currently scarce. Here, we describe the durability and broad-spectrum VOC immunity of a prefusion-stabilized spike (S) protein adjuvanted with liquid or lyophilized CoVaccine HT in cynomolgus macaques. This recombinant subunit vaccine is highly immunogenic and induces robust spike-specific and broadly neutralizing antibody responses effective against circulating VOCs (B.1.351 [Beta], P.1 [Gamma], and B.1.617 [Delta]) for at least three months after the final boost. Protective efficacy and postexposure immunity were evaluated using a heterologous P.1 challenge nearly three months after the last immunization. Our results indicate that while immunization with both high and low S doses shorten and reduce viral loads in the upper and lower respiratory tract, a higher antigen dose is required to provide durable protection against disease as vaccine immunity wanes. Histologically, P.1 infection causes similar COVID-19-like lung pathology as seen with early pandemic isolates. Postchallenge IgG concentrations were restored to peak immunity levels, and vaccine-matched and cross-variant neutralizing antibodies were significantly elevated in immunized macaques indicating an efficient anamnestic response. Only low levels of P.1-specific neutralizing antibodies with limited breadth were observed in control (nonvaccinated but challenged) macaques, suggesting that natural infection may not prevent reinfection by other VOCs. Overall, these results demonstrate that a properly dosed and adjuvanted recombinant subunit vaccine can provide protective immunity against circulating VOCs for at least three months.

Indexed as

COVID-19SARS-CoV-2Adjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibodies, ViralAntibody FormationCOVID-19 VaccinesHumansMacacaVaccines, SubunitAdjuvants, ImmunologicAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesVaccines, SubunitCoVaccine HTcynomolgus macaquesdelayed challengelyophilizedSARS-CoV-2subunit protein vaccine

Identifiers

PMID35263081
PMCPMC8938837
OpenAlexW4220972439

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.